Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 12 2025
0mins
Source: NASDAQ.COM
Quarterly Performance: Durect (DRRX) reported a quarterly loss of $0.07 per share, better than the expected loss of $0.13, and achieved revenues of $0.45 million, surpassing estimates by 39.69%. The stock has gained approximately 149.3% since the start of the year.
Future Outlook: The company's earnings outlook is mixed, with a current Zacks Rank of #3 (Hold), indicating expected performance in line with the market. Investors are advised to monitor upcoming earnings estimate revisions and industry trends that may impact stock performance.
Analyst Views on CATX
Wall Street analysts forecast CATX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CATX is 11.40 USD with a low forecast of 5.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.480
Low
5.00
Averages
11.40
High
18.00
Current: 2.480
Low
5.00
Averages
11.40
High
18.00
About CATX
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
